Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783403 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT03783403 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 206 participants.
The verdict
NCT03783403, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
Interventions
- DRUG Rituximab
- DRUG Cetuximab
- DRUG CC-95251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03783403
The ClinicalTrials.gov registry entry for NCT03783403 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT03783403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03783403 about?
NCT03783403 is a clinical study titled "A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers". The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.
What is the current status of trial NCT03783403?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2019-03-01. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT03783403?
The interventions under investigation include: Rituximab (DRUG), Cetuximab (DRUG), CC-95251 (DRUG).
Who is sponsoring clinical trial NCT03783403?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.